Syngeneic Mouse Models

The 4T1 syngeneic mouse tumor model is a widely used, immunocompetent, triple‑negative breast cancer model derived from BALB/c mice. It is characterized by aggressive primary tumor growth, spontaneous metastasis, and limited responsiveness to immune checkpoint inhibitors, making it a valuable system for evaluating refractory immuno‑oncology strategies and combination therapies.

• Immunocompetent system – Enables evaluation of therapies in the presence of a fully functional immune system
• Highly aggressive and metastatic – Mimics advanced breast cancer with lung metastases
• Checkpoint inhibitor–refractory – Ideal for testing novel IO combinations beyond PD‑1 monotherapy
• Well‑characterized benchmark model – Extensively used across immuno‑oncology research programs
  
  

The B16F10 tumor model is a widely used syngeneic melanoma model derived from murine melanoma cells and implanted in immunocompetent C57BL/6 mice. Characterized by aggressive tumor growth and poor responsiveness to immune checkpoint inhibition, this model serves as a stringent platform for evaluating novel immuno-oncology therapies. B16F10 is particularly valuable for investigating immune-resistant tumor biology, enabling robust assessment of therapeutic strategies designed to overcome resistance in the context of a fully functional immune system.

• • Immunocompetent system – Enables evaluation of therapies in the presence of a fully functional immune system
  • Native tumor–immune interactions – Supports assessment of checkpoint inhibitors and immune-modulating agents in vivo
  • Checkpoint inhibitor relevance – Facilitates evaluation of responses to anti-PD-1 and anti-CTLA-4 therapies
  • Immune resistance insights – Ideal for studying mechanisms of tumor immune evasion and refractory biology

The CT26 tumor model is a well-established syngeneic colorectal carcinoma model derived from murine colon carcinoma cells and implanted in immunocompetent BALB/c mice. Known for its high immunogenicity and strong responsiveness to immune checkpoint inhibitors, CT26 is widely used for evaluating immunotherapies and combination treatment strategies. This model provides a robust platform for studying tumor–immune system interactions, supporting both mechanistic research and translational development.

• Immunocompetent system – Enables evaluation of therapies in the presence of a fully functional immune system
• Checkpoint pathway relevance – Supports robust evaluation of PD-1 and CTLA-4 targeted therapies
• Immunogenic tumor microenvironment – Allows investigation of immune activation and TIL-driven responses
• Rational combination strategies – Enables development and optimization of combination immunotherapies
• Translationally predictive biology – Provides proof-of-concept insights into immune-mediated tumor response
  
  

The EL4 syngeneic tumor model is a lymphoma model derived from the EL4 cell line and propagated in immunocompetent C57BL/6 mice. This model supports evaluation of tumor progression and therapeutic interventions within a fully functional immune system.

EL4 is characterized as a refractory model to immune checkpoint inhibition, demonstrating minimal responsiveness to anti-PD-1 and anti-CTLA-4 therapies. Its consistent lack of response in both monotherapy and combination settings makes it a robust system for studying resistance mechanisms in immuno-oncology.

• • Immunocompetent environment – Enables assessment of therapies within an intact and functional immune system
  • Checkpoint inhibitor evaluation – Supports testing of anti-PD-1 and anti-CTLA-4 therapies and combinations
  • Physiological tumor-immune interplay – Maintains native interactions between tumor and immune cells
  • Versatile study design – Compatible with multiple dosing routes and therapeutic strategies
  • Benchmarking capability – Provides a well-defined non-responsive model for comparative studies

The MC38 syngeneic mouse tumor model is a well‑established, immunocompetent colorectal carcinoma model derived from C57BL/6 mice. Characterized by robust immune infiltration and strong responsiveness to immune checkpoint blockade, MC38 is widely used for evaluating immunotherapy mechanisms, combination strategies, and pharmacodynamic biomarkers.

• Highly immunogenic tumor microenvironment – Enables clear assessment of immune‑mediated anti-tumor activity
• Checkpoint inhibitor–responsive – Demonstrates strong responses to anti‑PD‑1, anti‑CTLA‑4, and combination therapy
• Ideal for mechanism validation – Frequently used as a benchmark for IO proof‑of‑concept studies
• Extensive translational data – Supports PD, biomarker, and immune profiling endpoints
  
  

The Renca syngeneic tumor model is a renal cancer model derived from the Renca cell line and established in immunocompetent mice. This model enables evaluation of tumor growth and therapeutic response within a fully functional immune system.

Renca is classified as a refractory model to immune checkpoint inhibition, demonstrating minimal response to standard anti-PD-1 and anti-CTLA-4 therapies in established tumor settings. Notably, therapeutic response is only observed when treatment is initiated prior to palpable tumor formation, making it a stringent model for assessing early intervention strategies.

• Immunocompetent system – Enables evaluation of therapies in the presence of a fully functional immune microenvironment
• Checkpoint inhibitor relevance – Supports assessment of anti-PD-1 and anti-CTLA-4 therapies and combinations
• Translatable immune interactions – Preserves tumor-immune system dynamics critical for immuno-oncology research
• Flexible study design – Compatible with a range of dosing strategies and therapeutic modalities
• Established benchmarking – Well-characterized responses to standard immunotherapies enable comparative studies